Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + propofol + sufentanil
- Development stage
- Unknown
- Lead developer
- Shiyou Wei
- Modality
- Small Molecules
- Administration
- Intranasal, Intravenous
01
Overview
This drug combination regimen consists of dexmedetomidine, propofol, and sufentanil, and is being investigated for procedural sedation in patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). Dexmedetomidine is a selective alpha-2 adrenergic agonist that provides sedation and analgesia without significant respiratory depression; in this specific protocol, it is administered via nasal spray as a premedication. Propofol is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of the GABA-A receptor. Sufentanil is a potent synthetic opioid analgesic that primarily targets mu-opioid receptors. The combination is designed to synergistically achieve deep sedation while reducing the required dosage of propofol, thereby minimizing side effects such as intraoperative hypoxemia and improving postoperative recovery quality.
- Other names
- Dexmedetomidine nasal spray combined with propofol and sufentanildexmedetomidine + propofol + sufentanil-Shiyou Wei-procedural sedation
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)ADRA2A (α2A)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on dexmedetomidine + propofol + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + propofol + sufentanil.